EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Jazz Pharmaceuticals's enterprise value is $10,990 Mil.
Jazz Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $3,834 Mil. Therefore, Jazz Pharmaceuticals's EV-to-Revenue for today is 2.87.
The historical rank and industry rank for Jazz Pharmaceuticals's EV-to-Revenue or its related term are showing as below:
JAZZ'
s EV-to-Revenue Range Over the Past 10 Years
Min: 2.87 Med: 5.56 Max: 12.18
Current: 2.87
During the past 13 years, the highest EV-to-Revenue of Jazz Pharmaceuticals was 12.18. The lowest was 2.87. And the median was 5.56.
JAZZ's EV-to-Revenue is ranked better than 71.54% of 1033
companies
in the Biotechnology industry
Industry Median: 7.66
vs JAZZ: 2.87
Jazz Pharmaceuticals EV-to-Revenue Historical Data
The historical data trend for Jazz Pharmaceuticals's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Jazz Pharmaceuticals's EV-to-Revenue
For the Biotechnology subindustry, Jazz Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jazz Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jazz Pharmaceuticals's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Jazz Pharmaceuticals's EV-to-Revenue falls into.
Jazz Pharmaceuticals's current Enterprise Value is $10,990 Mil.
Jazz Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $3,834 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jazz Pharmaceuticals (NAS:JAZZ) EV-to-Revenue Explanation
Jazz Pharmaceuticals's share price for today is $109.46.
Jazz Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $53.28.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jazz Pharmaceuticals EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Jazz Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Jazz Pharmaceuticals (Jazz Pharmaceuticals) Business Description
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
JAZZ has been successfully added to your 